Holter monitoring of ventricular arrhythmias in a randomised, controlled study of intravenous streptokinase in acute myocardial infarction

Dimitrios Alexopoulos, Rory Collins, Stamatios Adamopoulos, Richard Peto, Peter Sleight

Abstract
The occurrence of ventricular arrhythmias attributed to streptokinase treatment in acute myocardial infarction is not well defined. Holter monitoring was performed for 24 hours in 81 patients with suspected acute myocardial infarction randomised in a ratio of 2:1 to intravenous streptokinase 1.5 x 10^6 IU (n = 26) or placebo infusion (n = 26) 6-7 hours after the onset of symptoms. No episodes of ventricular fibrillation were recorded. For the whole 24 hour period and during the first three hours after the start of treatment the incidence and frequency of ventricular arrhythmias were similar in the patients randomised to streptokinase and to placebo. But when the results in patients randomised "early" after the onset of symptoms of suspected acute myocardial infarction were analysed separately, the frequency of abnormal complexes, pairs, runs, and repetitive arrhythmias seemed to be higher in patients allocated to streptokinase. This may reflect arrhythmias associated with reperfusion.

Streptokinase induced thrombolytic treatment of acute myocardial infarction can reopen occluded vessels, improve ventricular function, and prolong survival. It has, however, been suggested that reperfusion produced by thrombolytic treatment may be associated with an increase in the incidence of early ventricular arrhythmias. Conversely, because post-infarction ventricular arrhythmias are more common after larger infarcts, thrombolytic treatment, which seems to reduce infarct size, might be expected to decrease the overall incidence of arrhythmias. There are few controlled studies of the occurrence of ventricular arrhythmias in patients treated with fibrinolytic agents and those treated conventionally.

In the present study, 24 hour Holter monitoring was part of a double blind, placebo controlled randomised trial of intravenous streptokinase in acute myocardial infarction (ISIS-2 pilot) to assess the effects of thrombolytic treatment on ventricular arrhythmias. Arrhythmias occurring in the first few hours after the start of treatment (which might be related to reperfusion) and those occurring later during the first 24 hours (which might be related to infarct size) were assessed separately. Because some studies indicate that reperfusion rates may be inversely related to the time from onset of chest pain to the start of treatment, the influence of this delay on the incidence of ventricular arrhythmias was also investigated.

Patients and methods

PATIENTS
Between June 1983 and February 1985, 138 patients admitted to the John Radcliffe Hospital Coronary Care Unit were randomised in a placebo controlled study, details of which have been published elsewhere. Patients were eligible if the symptoms of suspected myocardial infarction had started less than 24 hours before and they had no clear indication for or contraindication to streptokinase, heparin, or aspirin (for example history of peptic ulcer, gastrointestinal bleed, stroke, bleeding disorder, recent surgery, resuscitation, or other injury, previous streptokinase treatment, aspirin allergy) and no life threatening condition other than myocardial infarction. A 2 x 2 factorial randomised study design was used. Two thirds of all patients were allocated randomly to treatment with intravenous streptokinase (1 500 000 IU) and one third to receive a matching placebo, started immediately and infused over about one hour in 20–100 ml of physiological saline. Half of all patients were also allocated randomly to receive enteric coated aspirin (325 mg every 48 hours) and half to receive matching placebo, one tablet each day for 28 days from a calendar pack, started immediately. Similarly, half of all patients were allocated randomly to receive heparin (1000 IU/h for 48 hours, starting 12 hours after the end of the streptokinase/placebo infusion) and half to receive no intravenous heparin, unless it was thought to be clearly indicated. In all other respects, physicians were free to use whatever additional treatment they considered necessary.

RECORDING AND ANALYSIS OF ARRHYTHMIAS
Holter tape recorders were available to start 24 hour electrocardiographic recording immediately before the start of trial treatment in 81 of the 138 Oxford patients (table 1). After the usual skin preparation modified V1 and V5 electrocardiographic leads were recorded on two channel Oxford Medilog II recorders. All patients had more than six hours recording. Two channel quantitative and qualitative electrocardiographic analysis was performed by a computerised non-triggered...
Table 1  Clinical characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>Streptokinase (n = 55)</th>
<th>Placebo (n = 26)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-randomisation data:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (yr)</td>
<td>61 (97)</td>
<td>57 (85)</td>
</tr>
<tr>
<td>Sex (% male)</td>
<td>78</td>
<td>73</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
<td>130 (205)</td>
<td>127 (128)</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>79 (174)</td>
<td>75 (126)</td>
</tr>
<tr>
<td>Previous myocardial infarction (%)</td>
<td>16</td>
<td>12</td>
</tr>
<tr>
<td>Diabetes mellitus (%)</td>
<td>16</td>
<td>0</td>
</tr>
<tr>
<td>Time from onset of pain (h)</td>
<td>6.7 (3.2)</td>
<td>6.6 (3.1)</td>
</tr>
<tr>
<td>Patients treated within 6 h</td>
<td>4.4 (1.3)</td>
<td>4.4 (1.5)</td>
</tr>
<tr>
<td>Patients treated later than 6 h</td>
<td>4.5 (3.8)</td>
<td>9.1 (2.4)</td>
</tr>
<tr>
<td>Infarct site:</td>
<td>44</td>
<td>46</td>
</tr>
<tr>
<td>Anterior-lateral (%)</td>
<td>56</td>
<td>54</td>
</tr>
<tr>
<td>Serum potassium on admission (mmol/l)</td>
<td>3.9 (0.5)</td>
<td>4.1 (0.4)</td>
</tr>
</tbody>
</table>

Post-randomisation data:

- Amiodarone (in the first 24 hours):
  - Streptokinase: 4
  - Placebo: 0

- Lignocaine (%): 2

- Peak enzyme activities during hospital stay:
  - AST (IU/l): 432 (279) Placebo (n = 26), 363 (270) Streptokinase (n = 55)
  - LDH (IU/l): 887 (736) Placebo (n = 26), 1157 (963) Streptokinase (n = 55)
  - Holter analysed (h): 23.1 (2.7) Placebo (n = 26), 21.7 (4.6) Streptokinase (n = 55)

AST, aspartate aminotransferase; LDH, lactate dehydrogenase.

Template system consisting of a Z80A processor and a DEC-LSI master, which had been used in our laboratory for the analysis of complex ventricular arrhythmias. The analysis was made without knowledge of the patient’s treatment regimen. The following definitions were used:

- (a) Abnormal complexes—abnormal QRS-shaped complexes with a coupling interval of >80% of the preceding RR interval.
- (b) Ventricular extrasystoles—abnormal QRS-shaped beats with a coupling interval ≤80% of the preceding RR interval.
- (c) Pairs—two consecutive abnormal QRS-shaped beats.
- (d) Runs—three or more abnormal QRS-shaped beats with a heart rate <120/min.
- (e) Ventricular tachycardia—three or more consecutive abnormal QRS-shaped beats with a rate ≥120 beats/min.
- (f) Repetitive arrhythmias—pairs, runs, and ventricular tachycardia.

When pairs, runs, and ventricular tachycardia were detected by the computer the analysis was automatically stopped and the operator confirmed the pattern. Because of the varying QT interval all ventricular extrasystoles with coupling interval ≤400 ms were screened carefully to identify and count the RR-on-T extrasystoles accurately.

Arrhythmias recorded during the 24 hour study period in patients allocated to a streptokinase infusion were compared with those in patients allocated to a placebo infusion. Arrhythmias occurring in the first three hours after treatment started were also compared with those occurring in the remaining 21 hours. Though the factorial design does in principle allow separate assessment of the effects of aspirin and of heparin, it was not the intent of this arrhythmia study to consider such effects in any detail. Furthermore, because heparin was started 13 hours after the start of Holter monitoring, any differences caused by heparin could only be expected during the later part of the Holter monitoring.

**Statistical analysis**

Baseline clinical characteristics were compared by the unpaired Student’s t test or χ² test as appropriate. We compared the incidence of arrhythmia (percentage of patients with arrhythmias) and their frequency per hour (total number of arrhythmias for each patient divided by the hours of recording) among patients allocated to streptokinase and those allocated to placebo by the χ² test and the Wilcoxon rank test, as appropriate. Values were expressed as mean (1 SD) or median and range.

**Results**

**Occurrence of arrhythmias**

No episodes of ventricular fibrillation were seen in this small study. Overall there were no significant differences between the streptokinase and the placebo groups in the percentage of patients with ventricular arrhythmias (table 2). Similarly, there were no significant differences between the treatment groups in the percentage of patients with arrhythmias within three hours of the start of thrombolytic treatment and the percentage with arrhythmia during the remaining 21 hours. In eight patients, there was a sudden increase in ventricular arrhythmias soon after the start of the infusion. These episodes lasted less than 90 min and were followed by infrequent ventricular arrhythmias during the remaining monitored hours (fig 1). This pattern was more common (but not significantly so) in the streptokinase group (seven patients (13%) than in placebo group (one patient (4%)).

When patients treated early (that is within six hours) after the onset of symptoms were considered separately, there was no significant difference in the percentage with arrhythmias in the different treatment groups (table 2).

Table 2  Percentage of patients with ventricular arrhythmias recorded on Holter monitoring

<table>
<thead>
<tr>
<th>All patients (n = 81)</th>
<th>≤6 h (n = 44)</th>
<th>6-24 h (n = 37)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormal complexes</td>
<td>93 (100)</td>
<td>58 (125)</td>
</tr>
<tr>
<td>Extrasystoles</td>
<td>93 (100)</td>
<td>93 (100)</td>
</tr>
<tr>
<td>Pairs</td>
<td>89 (93)</td>
<td>88 (93)</td>
</tr>
<tr>
<td>Runs</td>
<td>75 (88)</td>
<td>77 (89)</td>
</tr>
<tr>
<td>V tach</td>
<td>95 (95)</td>
<td>96 (95)</td>
</tr>
<tr>
<td>Repetitive</td>
<td>93 (93)</td>
<td>88 (88)</td>
</tr>
</tbody>
</table>

P, placebo; SK, streptokinase; V tach, ventricular tachycardia.
Figure 1 Distribution of abnormal complexes from a patient with sudden increase in arrhythmias shortly after the start of streptokinase infusion.

Figure 2 Percentage of patients and mean number of abnormal complexes, runs, and repetitive arrhythmias seen during the first 12 hours and 13–24 hours from randomisation. SK, streptokinase.

Table 3 Median frequency (range) per hour of ventricular arrhythmias

<table>
<thead>
<tr>
<th>All patients</th>
<th>≤6 h</th>
<th>6–24 h</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SK</td>
<td>P</td>
</tr>
<tr>
<td>Abnormal complexes</td>
<td>3–9 (0-2-390)</td>
<td>27 (0-1-76)</td>
</tr>
<tr>
<td>Extrasystoles</td>
<td>5-9 (0-3-889)</td>
<td>9 (0-5-497)</td>
</tr>
<tr>
<td>Pairs</td>
<td>2-0 (0-41)</td>
<td>0 (0-41)</td>
</tr>
<tr>
<td>Runs</td>
<td>3 (0-2)</td>
<td>0 (0-15)</td>
</tr>
<tr>
<td>V tach</td>
<td>3 (0-24)</td>
<td>0 (0-12)</td>
</tr>
<tr>
<td>Repetitive</td>
<td>8 (0-60)</td>
<td>0 (0-28)</td>
</tr>
</tbody>
</table>

*2p < 0.02; 12p < 0.01; 12p < 0.005.
See footnote to table 2 for abbreviations.

HOURLY FREQUENCY OF ARRHYTHMIAS
Overall there were no significant differences between the streptokinase and the placebo groups in the average hourly frequency of ventricular arrhythmias (table 3). The hourly frequency of arrhythmias recorded within three hours of the onset of treatment and during the remaining 21 hours of recording was similar in the treatment and placebo groups. But for patients treated within six hours of the onset of pain there were significant differences between the treatment groups in the frequency of abnormal complexes, of pairs, of runs, and of repetitive arrhythmias (table 3). This seemed to be largely the result of an increase in such arrhythmias during the first 12 hours after treatment (figs 2–4) and was not apparent among patients treated 6–24 hours after the onset of pain (table 3).

Discussion
There is little detailed information from Holter monitoring on the effects of fibrinolytic treatment on arrhythmias. To our knowledge, only two previous studies have attempted quantitative analysis of post-thrombolysis arrhythmias by continuous electrocardiographic monitoring. Willems et al used a low initial intravenous streptokinase dose regimen (250 000 IU initially, followed by 100 000 IU/hour for 24 hours) and they found no overall difference in the number of extrasystoles. Differences in baseline arrhythmias and in the use of antiarrhythmic agents, however, were considered by these workers to have limited the value of their study. More recently, in a study of 750 000 or 1 500 000 IU of intravenous...
streptokinase given over about 2.5 hours), Cercek et al reported on the percentage of patients with arrhythmias attributed to reperfusion defined by non-invasive indices. There was, however, no control group in this study with which to compare the patients given fibrinolytic treatment.

In the large GISSI trial conventional (that is non-Holter) electrocardiographic monitoring detected early arrhythmia in only 1-2% of the patients allocated to streptokinase treatment but in this trial the frequency of early arrhythmias was not recorded in the open-control patients. In a subgroup of 433 patients participating in GISSI, arrhythmic events were recorded by computerised coronary care or Holter monitoring during the first two hours after randomisation. No clear differences were demonstrated between the patients allocated to the streptokinase and control groups.

Ventricular fibrillation was not seen in any patient in the present Holter study, but this is not surprising given its small size. In the large ISIS-2 trial, the observed incidence of ventricular fibrillation during the first 24 hours after the start of treatment was similar in the patients allocated to streptokinase and placebo (2.8% v 2.8%, unpublished data), while ventricular fibrillation during hospital admission was somewhat less common in patients allocated to streptokinase (4.3% v 4.9%). A similar, non-significantly lower incidence of ventricular fibrillation in hospital was also seen in the GISSI and recent trials of other fibrinolytic agents.

The intention of the present Holter study was to assess the effects of streptokinase on arrhythmias in a randomised controlled study. Streptokinase did not seem to increase the overall percentage of patients with arrhythmia or the overall frequency of arrhythmias among the patients entered in the study, though there was a suggestion that streptokinase might be associated with an increased frequency of abnormal complexes, of runs, and of repetitive arrhythmias among patients treated early after the onset of pain. Because angiographic data were not available for patients in this study, this apparent excess of arrhythmias cannot be attributed definitely to myocardial reperfusion, though this seems to be a plausible hypothesis worthy of further study.

In this study intravenous streptokinase treatment seemed to have a low arrhythmogenic potential (and, indeed, larger studies suggest that serious arrhythmias may be less common with fibrinolytic treatment). Consequently, there may be little need for treatment with prophylactic antiarrhythmic agents in patients given fibrinolytic treatment, particularly in view of the lack of evidence for any benefits of these agents in the treatment of suspected acute myocardial infarction when fibrinolytic treatment is not used.

---

RC was supported by the British Heart Foundation. Hoechst (UK) and Behringwerke (Germany) provided supported. The study, however, was conducted, analysed, and interpreted independently of the companies.


